| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698133 | Clinical Oncology | 2017 | 13 Pages |
Abstract
Analysis of our data showed that CTLA-4 inhibitors (ipilimumab and tremelimumab) in a higher dose (10Â mg/kg) seem to be associated with a higher risk of treatment-related death compared with control regimens, whereas PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab and atezolizumab) do not cause the same risk. Clinicians have to be fully aware of these differential risks and council their patients appropriately.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, H. Oweira,